What is GeneDx Holdings Corp. Class A Common Stock's current stock price?

GeneDx Holdings Corp. Class A Common Stock (WGS) currently trades at USD 66.20. Track real-time price changes and historical performance on AllInvestView.

What sector is GeneDx Holdings Corp. Class A Common Stock in?

GeneDx Holdings Corp. Class A Common Stock operates in the Information Technology sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

GeneDx Holdings Corp. Class A Common Stock

🧾 Earnings Recap – Q3 2025

GeneDx's Q3 2025 results showcase robust financial performance with record growth, prompting an upward revision of revenue guidance to $425-$428 million for the year, supported by increased commercialization efforts and key executive hires.

Revenue growth remains strong with ongoing profitability, reflecting effective execution of the company’s strategic initiatives.
FDA granted breakthrough device designation for ExomeDx and GenomeDx, solidifying GeneDx's leadership in rare disease diagnostics.
Plans to nearly double the sales force to enhance penetration in pediatrician markets, with a focus on driving adoption of genomic testing.
Continued expansion into under-penetrated NICU markets, with a goal to significantly scale genetic testing in critical care settings.
Active involvement in innovative newborn screening initiatives underlines GeneDx’s commitment to proactive, equitable healthcare solutions.

View full recap page

GeneDx Holdings Corp. Class A Common Stock Analysis (WGS)

United States Information Technology Official Website Stock

Is GeneDx Holdings Corp. Class A Common Stock a good investment? GeneDx Holdings Corp. Class A Common Stock (WGS) is currently trading at 66.20 USD. Market analysts have a consensus price target of 156.67 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 724.64. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: GeneDx Holdings Corp. Class A Common Stock is expected to release its next earnings report on May 13, 2026. The market consensus estimate for Forward EPS is 2.06.

Investor FAQ

Does GeneDx Holdings Corp. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is GeneDx Holdings Corp. Class A Common Stock?

GeneDx Holdings Corp. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 13, 2026. The company currently has a trailing EPS of -0.73.

Company Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Split Date	Split Ratio to 1
May 4, 2023	0.030000

Split Date

Split Ratio to 1

May 4, 2023

0.030000

GeneDx Holdings Corp. Class A Common Stock WGS Open GeneDx Holdings Corp. Class A Common Stock in new tab

GeneDx Holdings Corp. Class A Common Stock

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features